Physician profile
Kenneth B Sumner
NPI 1073653275
$11,602.80
in general payments reported to CMS, 2019-2025
28 companies · $3,066 in 2025
The $3,066 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $206 · 2021: $218 · 2022: $1,183 · 2023: $2,959 · 2024: $3,225 · 2025: $3,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,249.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,055.30 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,108.33 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Lundbeck LLC | $1,011.36 | 2019-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $934.12 | 2020-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $879.17 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $854.67 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $626.97 | 2022-2025 | Caplyta |
| Tris Pharma INC | $587.90 | 2022-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $519.86 | 2022-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $442.12 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Almatica Pharma LLC | $434.19 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Vanda Pharmaceuticals INC. | $374.72 | 2022-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $338.26 | 2019-2025 | Ingrezza |
| Noven Therapeutics, LLC | $317.39 | 2023-2025 | Xelstrym, Secuado |
| Corium, LLC | $258.05 | 2022-2024 | Azstarys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $169.81 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $139.75 | 2022-2025 | Trintellix |
| Shire North American Group INC | $124.99 | 2019 | |
| Allergan, INC. | $98.18 | 2019-2020 | |
| Bausch Health US, LLC | $89.51 | 2019-2024 | Aplenzin, Wellbutrin |
| Acadia Pharmaceuticals INC | $56.69 | 2022 | |
| Bioxcel Therapeutics, INC. | $54.09 | 2023 | Igalmi |
| Jazz Pharmaceuticals INC. | $27.67 | 2022 | |
| Brainsway USA INC | $24.38 | 2024 | Brainsway Deep Tms System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.18 | 2024 | |
| Avanir Pharmaceuticals, INC. | $19.64 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.67 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Sumner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.